BCAX 8-K 2026-11-09

Bicara Therapeutics Inc. (BCAX) 8-K dated 2026-11-09 — accession 0001628280-26-071886.

Bicara Therapeutics Inc. (BCAX) is a biotechnology company listed on NASDAQ.

BCAX: Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Pr…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Income-statement cache for BCAX is thin on this filing URL. We will not invent exhibit numbers.

Not investment advice. The BCAX SEC hub lists recent forms. The stock page is the research view.

Guidance: expects to have results from this study by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC.

Why it matters

expects to have results from this study by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC.